Phase 2 proof-of-concept trial with AMO Pharma investigative therapy AMO-02 now underway at 17 sites across Canada; 120 patients expected to enroll LONDON, Sept. 8, 2025 /PRNewswire/ — AMO Pharma Limited (“AMO Pharma”), a privately held clinical-stage specialty biopharmaceutical company focusing on rare genetic disorders with limited or no treatment options, today announced […]